Welcome to our dedicated page for Prothena news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena stock.
Prothena Corporation Plc (PRTA) is a clinical-stage biotechnology company advancing novel antibody therapies for complex diseases involving protein misfolding. This news hub provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic partnerships shaping the company's trajectory in amyloidosis, neurodegenerative disorders, and inflammatory disease research.
Access authoritative reporting on PRTA's pipeline developments, including detailed coverage of Phase 1-3 trial outcomes, FDA interactions, and collaborative research initiatives. Our curated news collection enables stakeholders to track progress across therapeutic areas where Prothena specializes: targeting pathogenic proteins in Alzheimer's disease, Parkinson's disease, and rare amyloidosis conditions.
Key updates include earnings announcements, scientific conference presentations, intellectual property developments, and partnership expansions. Bookmark this page for structured access to press releases, peer-reviewed publication highlights, and expert analyses of Prothena's innovative immunotherapies.
Prothena (NASDAQ: PRTA) announced that Bristol Myers Squibb has acquired an exclusive global license for PRX019, a potential treatment for neurodegenerative diseases, resulting in an $80 million payment to Prothena. The FDA cleared PRX019's investigational new drug application in December 2023, and Prothena plans to start a Phase 1 clinical trial by late 2024. The collaboration with Bristol Myers Squibb aims to advance PRX019 as part of Prothena's broader portfolio, with potential additional milestone payments totaling up to $617.5 million and tiered royalties on net sales.
Prothena plc (NASDAQ:PRTA) reported net cash used in operating and investing activities of $73.2 million in Q1 2024 with a cash position of $548.7 million. The company advanced potential Alzheimer's and Parkinson's disease treatments, strengthened its leadership position in the amyloidosis community, and appointed Daniel G. Welch to the Board of Directors. Financially, Prothena reported a net loss of $72.2 million, total revenue of $0.1 million, R&D expenses of $64.1 million, and G&A expenses of $17.5 million for Q1 2024.
Prothena plc (NASDAQ:PRTA) will report its first quarter 2024 financial results on May 8, 2024, after the close of the U.S. financial markets. The company, a late-stage clinical biotechnology firm focusing on investigational therapeutics, will not host a conference call along with the results release.
FAQ
What is the current stock price of Prothena (PRTA)?
What is the market cap of Prothena (PRTA)?
